Seattle, WA -- (SBWIRE) -- 11/07/2019 -- According to the American Journal of Nephrology, 2015, Australia has the highest numbers of annual renal biopsy rates (215 persons/million person/year) followed by Finland (176 persons/million person/year) and U.S. (175 persons/million person/year). The increased numbers of biopsy procedures likely to fuel the growth of the tissue diagnostic market, in the near future.
Tissue diagnosis is a diagnostic test which is used to detect the disease through biopsy, in which sample is taken out from the affected area or tumor for further diagnosis. A biopsy is mainly done to look for cancer detection or to detect rejection of transplanted organ draft. This test is basically performed to detect the nature of cells whether it is cancerous or non-cancerous tissue, which can be detected through CT-scan or x-rays. Biopsy tests can be classified as endoscopic biopsy, bone marrow biopsy, skin biopsy, kidney biopsy, liver biopsy, and prostate biopsy. It can be done by using needle biopsy, CT guided biopsy, ultrasound biopsy, and surgical biopsy for the tissue diagnostic.
Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1112
The growing prevalence of various cancer incidences is a major driving factor boosting the tissue diagnostic market. According to the American Cancer Society (ACS), 1.6 million new cases of cancer diagnosed in the U.S., in 2016. Moreover, growing research funding in cancer treatment and risinghealthcare expenditure is likely to show a gradual rise in the tissue diagnostic market. National Cancer Institute, in 2015, spends US$ 4,480 million on various types of cancer research which includes breast cancer, colorectal cancer, cervical cancer, liver cancer, lung cancer, leukemia, ovarian cancer and uterine cancer.
According to the United States Cancer Statistics report published in 2014 by the Centers for Disease Control and Prevention (CDC), between 1999 and 2014, more than 1600 people a day, died due to the cause of cancer. Although screening tests help to detect cancer condition at an early stage, data from Healthy People 2020, an initiative from the Department of Health and Human Services, reveals that the screening rate is still below the national targets set. Combined data collected from CDC and National cancer institute (NCI) focus on the top 3 cancer incidences in males and females. In male prostate cancer the incidence rate is higher, whereas female's breast cancer is popular in women, followed by lung and colon cancer respectively in both males and females.
Advancement in tissue diagnostic process for the efficient diagnostic testing such as Fluorescence in situ hybridization (FISH), Immunohistochemistry (IHC) and In situ hybridization (ISH) opens the opportunity to grow tissue diagnostic markets in the future. In September 2017, researchers at the The University of Texas developed a new way of diagnosis by creating pen named as "MasSpec Pen", which is handheld devices able to differentiate healthily tissue and tumor tissue in just 10 seconds, more than 150 times quicker than existing technology. This new tool provides improvement in cancer treatment and minimizes the risk of recurrence by offering precise diagnostic information, which eventually fuels the market growth of tissue diagnostic.
The PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/1112
Key players operating in the tissue diagnostic market are Biocare Medical, Agilent technologies, Thermo Fisher Scientific, Sigma-Aldrich, Roche Diagnostics, Danaher corp., Biogenex Laboratories, Life Technologies and Abbott laboratories.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.a
Contact Us:
Name: Mr. Raj Shah
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com